Chronic Respiratory Disease最新文献

{"title":"Cutoff points for sedentary behavior and their capacity to predict mortality in individuals with COPD: A 12- year follow-up study.","authors":"Lais Santin, Humberto Silva, Thais Moçatto Tofoli, Letícia Medeiros, Karina Couto Furlanetto, Fabio Pitta","doi":"10.1177/14799731251366956","DOIUrl":"https://doi.org/10.1177/14799731251366956","url":null,"abstract":"<p><p>ObjectiveThis study aimed to identify the usefulness and compare three cutoff points of sedentary behavior (i.e., >8.5 h/day in sedentary time [ST], >70% of the awake time spent in ST, and <4300 steps/day) as predictors of all-cause mortality over a 12-years follow-up period in individuals with stable COPD.MethodsBaseline-only data from 92 individuals with COPD assessed for admission to pulmonary rehabilitation were analyzed.ResultsCox multivariate regression models identified the cutoff point of ST >8.5 h/day as an independent predictor of mortality after adjusting for confounders (hazard ratio 1.23, 95% CI 1.021 - 1.589, P = 0.02). The other two cutoffs were not significant.ConclusionAmong different cutoffs indicating sedentary behavior, ST >8.5 h/day was identified as an independent indicator of higher mortality risk in a 12-years follow-up period in individuals with stable COPD, indicating a 23% higher mortality risk in comparison to those who present ST <8.5 h/day.</p>","PeriodicalId":10217,"journal":{"name":"Chronic Respiratory Disease","volume":"22 ","pages":"14799731251366956"},"PeriodicalIF":2.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12375146/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144945040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlations between exercise oxygen consumption, lung function, image findings, and quality of life in adults with post-tuberculosis lung disease.","authors":"Marcela Pinto Venâncio Lourenço da Silva, Paulo Victor Leandro da Silva Pinto, Iasmim Maria Pereira Pinto Fonseca, Lucas Silva de Lima, Alícia Sales Carneiro, Walter Costa, Ana Paula Santos, Agnaldo José Lopes","doi":"10.1177/14799731251345492","DOIUrl":"10.1177/14799731251345492","url":null,"abstract":"<p><p>The aim of this study is to evaluate the correlations of peak oxygen uptake (VO2peak) with lung mechanics, radiographic abnormalities, and quality of life (QoL) in adults with post-tuberculosis lung disease (PTLD). This is a cross-sectional study in which 60 adults with PTLD underwent a cardiopulmonary exercise test (CPET). Additionally, the following assessments were performed: spirometry, impulse oscillometry (IOS), chest X-ray (CXR), and QoL using the WHOQOL-BREF. The mean peak oxygen uptake (VO_2peak) was 16.1 ± 6.8 ml/kg/min. There were positive correlations between VO_2peak and several parameters, including height, physical-WHOQOL-BREF, and forced vital capacity (FVC). There were negative correlations between VO_2peak and several parameters, including age, heterogeneity of resistance between 5 and 20 Hz, frequency response (Fres), and reactance-area. In IOS, patients with small airway disease (SAD) had a lower VO_2peak. Regarding CXR, only cavitation and nodular opacities were associated with a lower VO_2peak. In multivariate analysis, FVC, age, male sex, and Fres explained 65.2% of the variability in VO_2peak. In conclusion, there is a relationship between VO_2peak and lung mechanics in patients with PTLD. In these patients, IOS is able to detect more pulmonary mechanical alterations than spirometry, including those reflecting SAD. Thus, the use of both CPET and IOS may aid in the monitoring of patients with PTLD.</p>","PeriodicalId":10217,"journal":{"name":"Chronic Respiratory Disease","volume":"22 ","pages":"14799731251345492"},"PeriodicalIF":3.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12099090/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144126835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative analysis of pulmonary function decline in patients undergoing bronchoscopic lung volume reduction with endobronchial valves versus conservative treatment in emphysema management: A longitudinal coarsened exact matched analysis.","authors":"Johannes Wienker, Kaid Darwiche, Rüdiger Karpf-Wissel, Dirk Westhölter, Erik Büscher, Sebastian Zensen, Johannes Haubold, David Kersting, Hubertus Hautzel, Josef Homola, Christian Taube, Marcel Opitz, Marc Struß","doi":"10.1177/14799731251350709","DOIUrl":"10.1177/14799731251350709","url":null,"abstract":"<p><p>BackgroundChronic obstructive pulmonary disease (COPD) and emphysema display a chronic and progressive disease for the individual patient. The forced expiratory volume in one second (FEV₁) is declining with age as displayed in the Fletcher-Peto curve. Despite established benefits of bronchoscopic lung volume reduction (BLVR) using endobronchial valves (EBVs), long-term data suggest a gradual reduction in the magnitude of these benefits.PurposeThis study aimed to compare the rate of lung function change in emphysema patients undergoing BLVR versus those receiving conservative management, utilizing coarsened exact matching to ensure balanced baseline characteristics.Patients and MethodsIn this retrospective single center study data between 2015 and 2021 was analyzed. BLVR patients achieving significant volume reduction (≥563 mL) were matched to conservatively managed controls based on age, sex, BMI, and smoking history. Pulmonary function changes after successful BLVR with valves, including forced expiratory volume in one second (FEV₁) and residual volume (RV), were monitored and analyzed over a 3-year period.ResultsA total of 60 patients, evenly distributed between the two groups (30 each), were included in the analysis. Median FEV₁ change was -0.063 L/year for BLVR patients and -0.066 L/year for controls. No statistically significant differences in annual FEV₁ and RV changes were observed (-0.07 vs -0.08, <i>p</i> = 0.492; -0.07 vs -0.07, <i>p</i> = 0.569; -0.05 vs -0.04, <i>p</i> = 0.636 at follow-ups in years 1, 2, and 3, respectively for FEV₁ and +0.20 vs +0.25, <i>p</i> = 0.643; +0.80 vs +0.65, <i>p</i> = 0.960; +1.0 vs +0.85, <i>p</i> = 0.963 at follow-ups in years 1, 2, and 3, respectively for RV).ConclusionIn this matched cohort analysis, no significant differences in annual changes in FEV₁ or RV progression were observed between patients after successful BLVR with valves and patients under conservative treatment. The results indicate that COPD progression is the main factor for the decline in functional improvement after successful BLVR with valves.</p>","PeriodicalId":10217,"journal":{"name":"Chronic Respiratory Disease","volume":"22 ","pages":"14799731251350709"},"PeriodicalIF":3.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12163258/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144274294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of individual nutritional therapy during inpatient pulmonary rehabilitation in patients at risk for malnutrition and sarcopenia - a randomized controlled trial.","authors":"Marco Coiro, Andrea Zurfluh, Undine Lehmann, Patrick Brun, Anke Scheel-Sailer, Hansueli Tschanz, Ann van Hoof, Matthias Wilhelm, Thimo Marcin","doi":"10.1177/14799731251350692","DOIUrl":"10.1177/14799731251350692","url":null,"abstract":"<p><p>BackgroundMalnutrition and sarcopenia are common in inpatient rehabilitation, however individual nutritional therapy (iNT) is often underutilized. This study aimed to assess the effect of iNT on nutrition and muscular health.MethodPatients with chronic obstructive pulmonary disease (COPD) or post-pneumonia at risk for malnutrition and sarcopenia undergoing inpatient rehabilitation were enrolled. The control group received usual care including enriched food and educational group sessions on nutrition. The intervention group received additional counselling by a dietician twice a week. Both groups received individualized physiotherapy and self-management coaching, endurance exercise sessions on 5 days and strength training sessions on 2-3 days per week as part of the clinical routine. Primary outcomes were changes in energy and protein intake, assessed via menu consumption and macronutrient analysis. Secondary outcomes included handgrip strength, muscle mass by bioimpedance analysis, and physical performance measured by the timed-up-and-go test.ResultsTwenty-six patients per group (median age of 72 years, 60% men, 52% COPD) were included. Energy and protein intake increased significantly more in the intervention group with a 309 kcal and 16 g compared to -53 kcal and -1 g in the control group (<i>p</i> = 0.001 for group differences). Handgrip improved more in the intervention group by a median of 1 kg (<i>p</i> = 0.007), without group differences in muscle mass or physical performance.ConclusionINT effectively increased energy and protein intake in patients at risk of malnutrition and sarcopenia undergoing 3 weeks of pulmonary rehabilitation, with a positive impact on prognostic handgrip strength.Trial registrationThe study was registered by the US National Institutes of Health (ClinicalTrials.gov). # NCT05096013.</p>","PeriodicalId":10217,"journal":{"name":"Chronic Respiratory Disease","volume":"22 ","pages":"14799731251350692"},"PeriodicalIF":2.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12174794/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144301218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prevalence of metabolic syndrome in chronic obstructive pulmonary disease: A systematic review and meta-analysis.","authors":"Hassan Alrabbaie, Mohammad Al-Wardat, Mohammad Etoom, Marla Beauchamp, Roger Goldstein, Dina Brooks","doi":"10.1177/14799731251346194","DOIUrl":"10.1177/14799731251346194","url":null,"abstract":"<p><p>ObjectiveMetabolic syndrome (MetS) is a cluster of factors that increase the risk of cardiovascular disease and type 2 diabetes. It is highly prevalent among patients with Chronic Obstructive Pulmonary Disease (COPD). This systematic review and meta-analysis assessed MetS prevalence in COPD patients, focusing on variations by gender, diagnostic criteria, and disease severity.MethodsWe systematically searched MEDLINE, Embase, Scopus, and CINAHL. Two reviewers independently extracted data using a standardized form, and study quality was assessed with the Joanna Briggs Institute checklist. Prevalence rates, with 95% confidence intervals (CI), were calculated using a random-effects model. Subgroup analyses by sex, COPD severity, and MetS components were conducted.ResultsForty-two studies, including 54,278 COPD patients, were analyzed. Overall, the prevalence of MetS was 37% (95% CI: 30.6-43.8%; I² = 99.03%, p < 0.001). Prevalence was 48% (95% CI 38.1 to 57.5) in males and 43% (95% CI 38.3 to 48.8) in females. Among studies using the Alberti definition, the pooled prevalence was 46% (95% CI 35.6 to 56.3). Patients with GOLD stage II showed a prevalence of 44% (95% CI 37.3 to 50.4). The most common MetS components were Hypertension 58% (95% CI 47.2 to 68.0) and increased waist circumference 51% (95% CI 37.1 to 64.6).ConclusionMetS is highly prevalent among COPD patients. Standardized diagnostic criteria are needed, and early detection with integrated care is recommended.</p>","PeriodicalId":10217,"journal":{"name":"Chronic Respiratory Disease","volume":"22 ","pages":"14799731251346194"},"PeriodicalIF":2.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12106998/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144141865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of implementation science to qualitatively identify implementation determinants of COPD practice guidelines in primary care.","authors":"Deepa Raghavan, Karen L Drummond, Sonya A Sanders, JoAnn Kirchner","doi":"10.1177/14799731251314870","DOIUrl":"10.1177/14799731251314870","url":null,"abstract":"<p><p><b>Objectives:</b> Chronic Obstructive Pulmonary Disease (COPD) is a progressive respiratory disease with high morbidity and mortality. COPD guidelines (CPG) are greatly underutilized and studies attempting to improve this practice gap have yielded inconsistent results. We hypothesize that using implementation science can provide a detailed understanding of these practice gaps and the reasons behind them. <b>Methods:</b> Since primary care (PC) manages the bulk of COPD patients, in this pilot study, we use principles of implementation science to systematically explore the reasons for this implementation gap in a PC setting. We used the Consolidated Framework of Implementation Science (CFIR), a determinant framework to design semi-structured interview guides to conduct multistakeholder interviews to explore the barriers and facilitators to four key COPD-CPG with known poor uptake: inhaler education, spirometry, pulmonary rehabilitation and COPD-specific patient education from patient and provider perspectives. Qualitative analysis was performed using rapid analysis. <b>Results:</b> Seventeen respondents including both, patients and providers were interviewed. All these COPD-CPG were rated as 'highly important' suggesting that perceived importance alone is insufficient to bridge gaps in uptake. Respondents were least familiar with pulmonary rehabilitation. Physician time constraint was a significant reported barrier. There exist multilevel contextual barriers to each of these COPD-CPG. <b>Discussion:</b> To increase uptake of COPD guidelines, implementation efforts that address multilevel barriers and promote collaborative care by use of non-physician resources are likely to have higher buy-in and greater chances for success.</p>","PeriodicalId":10217,"journal":{"name":"Chronic Respiratory Disease","volume":"22 ","pages":"14799731251314870"},"PeriodicalIF":3.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11800250/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143254971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Longer daily oxygen use associates with more adverse events, symptoms, and worse health status in long-term oxygen therapy.","authors":"Filip Björklund, Magnus Ekström","doi":"10.1177/14799731251366962","DOIUrl":"10.1177/14799731251366962","url":null,"abstract":"<p><p>IntroductionUse of long-term oxygen therapy (LTOT) for more than 15 h per day does not reduce mortality or hospitalizations, but may increase the risk of adverse events. We evaluated the relationship between daily oxygen use duration and adverse events, symptoms, and health status in patients on LTOT.MethodsThis was a cross-sectional survey study of a random sample (<i>N</i> = 650) of adults with ongoing LTOT in Sweden. Oxygen use (h/day) was reported, and associations were analyzed with adverse events, symptom severities (revised Edmonton Symptom Assessment System), sleep duration and quality, and health status (COPD assessment test [CAT]).ResultsIn total, surveys from 204 patients were analyzed; 60% female, mean age 75.3 (SD 8.7) years. Swedevox baseline characteristics were similar between sampled respondents and non-respondents. Patients reporting 24 h of daily oxygen use (53.4%) also reported a higher number of total adverse events, higher ratings of dyspnea, depression and anxiety, and worse health status, compared to those reporting fewer hours of oxygen use. A longer daily duration of oxygen use also associated with a higher number of experienced adverse events, higher ratings of dyspnea and anxiety, and worse rated health status in crude and adjusted linear regression models. No associations were seen between oxygen use duration and sleep quality or duration.ConclusionMore adverse events, a higher severity of some symptoms, and worse health status are seen among patients with a longer daily duration of oxygen use. Further research is needed to establish evidence of causality.</p>","PeriodicalId":10217,"journal":{"name":"Chronic Respiratory Disease","volume":"22 ","pages":"14799731251366962"},"PeriodicalIF":2.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12334815/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144798330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Telomere biology disorder associated lung disease- case report of a <i>TERT</i> gene variant as the cause of pleuroparenchymal fibroelastosis.","authors":"Julian Pott, Ann-Sophie Höing, Alexander Volk, Lennart Well, Fabian Beier, Dirk Lebrecht, Lars Harbaum, Hans Klose, Tim Oqueka","doi":"10.1177/14799731251370357","DOIUrl":"10.1177/14799731251370357","url":null,"abstract":"<p><p>Case presentationDescription of a patient with a progressive destructive lung disease resembling pleuroparenchymal fibroelastosis, liver cirrhosis and bone marrow changes. Genetic workup identified a rare heterozygous coding variant in the <i>TERT</i> (telomerase reverse transcriptase) gene c.472 C>T; p.(Leu158Phe) and telomere length testing revealed significant telomere shortening, supporting the diagnosis of telomere biology disorder (TBD).DiscussionTBD is an underrecognized cause of interstitial lung disease (ILD). It is a heterogeneous disease that can affect different organs, including lungs, liver and bone marrow. Genetic testing in ILD is crucial for early diagnosis, risk assessment, and family screening. Identifying this variant enables targeted genetic testing for relatives, allowing preventive measures and lifestyle modifications.</p>","PeriodicalId":10217,"journal":{"name":"Chronic Respiratory Disease","volume":"22 ","pages":"14799731251370357"},"PeriodicalIF":2.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12423533/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145029070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cut-offs for daily step counts are associated with measures of health status in people with COPD: An observational study.","authors":"Juliana M B Dos Santos, Fabiano F de Lima, Caroline M Censo, Eloise A Santos, Juliana T Ito, Rafaella F Xavier, Regina M Carvalho-Pinto, Celso R F Carvalho","doi":"10.1177/14799731251345490","DOIUrl":"10.1177/14799731251345490","url":null,"abstract":"<p><p><b>Objective:</b> To explore the associations between preestablished daily step count cut-offs and health status, dyspnoea, and psychosocial distress in individuals with COPD. <b>Methods:</b> A cross-sectional analysis was performed on 252 individuals with COPD. PADL was objectively assessed using a triaxial accelerometer, and participants were categorized as physically active or inactive according to three daily step count cut-offs previously reported for individuals with COPD (4,300, 4,580, and 5000 steps/day). Health status was measured via the COPD Assessment Test (CAT) and Clinical COPD Questionnaire (CCQ), dyspnoea was assessed via the modified Medical Research Council (mMRC) scale, and psychosocial distress was evaluated via the Hospital Anxiety and Depression Scale (HADS). <b>Results:</b> Meeting the cut-off of 5000 steps/day was associated with lower CAT scores and depressive symptoms. Meeting the cut-off of 4300 steps/day was associated with less dyspnoea (mMRC < 2). No significant associations were observed between anxiety symptoms and step count cut-offs. The 4580 steps/day cut-off did not predict health outcomes. <b>Conclusions:</b> A daily step count of 5000 steps appears to be the most effective threshold for distinguishing between different levels of health status and depressive symptoms in individuals with COPD. These findings suggest that step counts can be used as a clinical health indicator in this population. Future interventional studies are needed to confirm our findings.</p>","PeriodicalId":10217,"journal":{"name":"Chronic Respiratory Disease","volume":"22 ","pages":"14799731251345490"},"PeriodicalIF":3.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12117231/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144149252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differences in COPD management across clinician type: Maintenance treatment habits and patient characteristics among US pulmonologists, internal/family medicine physicians, nurse practitioners, and physician assistants.","authors":"Mario Castro, Kevin C Carney, Steven M Romanelli, Amy L Dixon, Maryam Q Abdul Rahman, Kavita Aggarwal, Barbara P Yawn","doi":"10.1177/14799731251346191","DOIUrl":"10.1177/14799731251346191","url":null,"abstract":"<p><p>ObjectivesTreatment recommendations for chronic obstructive pulmonary disease (COPD) are based on single or combination long-acting bronchodilator therapy (β₂-agonists [LABAs] or muscarinic receptor antagonists [LAMAs]), with inhaled corticosteroids (ICS) for those at risk of exacerbations. This study evaluated differences in patient characteristics and treatment patterns among US clinicians.MethodsMedical record data for patients with COPD were abstracted via a retrospective cross-sectional survey by pulmonologists, internal/family medicine physicians, nurse practitioners (NPs) and physician assistants (PAs).ResultsData on 700 patients were collected from 175 clinicians: 100 pulmonologists, 45 internal/family medicine physicians, 30 NP/PAs. Respondents classified patients as having Mild (11%), Moderate (51%), or Severe/Very Severe (38%) COPD, with highest perceived disease burden for patients with Severe/Very Severe COPD. Dual therapies were prescribed differently according to clinician type. Internal/family medicine physicians and NP/PAs prescribed LABA/ICS to a significantly higher proportion of patients than pulmonologists, who favored use of dual bronchodilator therapy. Regardless of clinician type, COPD management was complex, with patients starting and transitioning to multiple treatments throughout their care.ConclusionDifferences in COPD treatment patterns exist across US clinicians. Despite current maintenance treatment, COPD had a profound impact on patients, indicating a need for improved therapies for COPD.</p>","PeriodicalId":10217,"journal":{"name":"Chronic Respiratory Disease","volume":"22 ","pages":"14799731251346191"},"PeriodicalIF":3.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12141797/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144233368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}